3 assets in Wolfram Syndrome

Therapeutic assets addressing Wolfram Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Depakine Wolfram Syndrome	Centre d'Etude des Cellules Souches	P2	CCC (53)
Taurursodiol Wolfram Syndrome	Amylyx Pharmaceuticals Inc.	P2	CCC (53)
Tirzepatide Wolfram Syndrome	Ospedale San Raffaele	P2	CCC (53)